Drug Landscape ›
SERTRALINE ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 66,754
Most-reported reactions
Drug Ineffective — 8,508 reports (12.75%) Nausea — 8,444 reports (12.65%) Fatigue — 7,597 reports (11.38%) Headache — 6,809 reports (10.2%) Diarrhoea — 6,679 reports (10.01%) Anxiety — 6,038 reports (9.05%) Dizziness — 6,036 reports (9.04%) Off Label Use — 5,740 reports (8.6%) Drug Interaction — 5,538 reports (8.3%) Depression — 5,365 reports (8.04%)
Source database →
SERTRALINE in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is SERTRALINE approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for SERTRALINE in United States?
Marketing authorisation holder not available in our data.